Where does Longhorn Vaccines and Diagnostics, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Longhorn Vaccines and Diagnostics, LLC ranks #10,672 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Longhorn Vaccines and Diagnostics, LLC hold?

Longhorn Vaccines and Diagnostics, LLC holds 29 US utility patents granted between 2015 and 2025, spanning 10 technology areas.

What is Longhorn Vaccines and Diagnostics, LLC's Innovation Score?

Longhorn Vaccines and Diagnostics, LLC has an Innovation Score of 40.4 out of 100 (top 36% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Longhorn Vaccines and Diagnostics, LLC's patent grant rate increasing or decreasing?

Longhorn Vaccines and Diagnostics, LLC's recent grant velocity is -47% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Longhorn Vaccines and Diagnostics, LLC's patents?

Longhorn Vaccines and Diagnostics, LLC's patents average 28.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Longhorn Vaccines and Diagnostics, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Longhorn Vaccines and Diagnostics, LLC

Q: What technology areas does Longhorn Vaccines and Diagnostics, LLC focus on?

Longhorn Vaccines and Diagnostics, LLC's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 21 patents, ranking #514 of 4,144 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

USPTO PatentsView assignee record - 29 granted patents across 10 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Longhorn ranks #10,672 of 49,997 tracked US assignees by granted-patent volume, with 29 patents across 10 technology areas.

#10,672
of 49,997 US assignees by volume: Top 36%
by Innovation Score (40.4/100): 28.2
avg claims per patent: -47%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10672 · US Corporation #10,672 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 29 grants
UPPER-Q #10,672/49,997
PHOTO-FINISH Leica Camera
CPC-FOCUS C12N · 10 areas
INNOV-PAR 40.4/100
CLAIMS-DENSE 28.2 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -47% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Leica Camera AG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Longhorn’s 40.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.7 pts (29%) Velocity 2.5 pts (6%) Breadth 11.2 pts (28%) Claim depth 15.0 pts (37%)

Qualcomm Incorporated · highest

85
ADA Carbon Solutions · near

40
Heesung Catalysts · near

40
Longhorn Vaccines… · this assignee

40
Qatar Foundation · near

40
Tetra Tech · near

40
3D Lighting… · lowest

7

What this shows Longhorn's Innovation Score is 40.4/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Longhorn?

Each dot is one of Longhorn’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Longhorn’s own 28.2 claims/patent is ABOVE the 14.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Longhorn vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Longhorn's grants concentrate

Longhorn Vaccines and Diagnostics, LLC is a focused PatentsView assignee: 10 CPC subclasses with 72.4% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2017 (6 grants) versus a trough of 1 in 2024. By volume, Longhorn sits between Locix, Inc. and Luxembourg Patent Company S.A..

Longhorn's three-year grant acceleration

Longhorn Vaccines and Diagnostics, LLC shows 3 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Locix

29
Leica Camera

29
Lifescan

29
Linde Hydraulics…

29
Lucyd

29
Lumentum Technolo…

29
Lutronic Vision

29
Luxembourg Patent

29
Longhorn Vaccines… ◀

29

What this shows Longhorn holds 29 patents at rank #10,671, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Longhorn

By rank, the assignees closest to #10,671 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Longhorn's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Longhorn, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Longhorn ranks #514 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Heesung Catalysts Corporation 40 ADA Carbon Solutions, LLC 40 Qatar Foundation 40 Tetra Tech, Inc. 40

Longhorn's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 36% higher than 64% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Longhorn Vaccines and Diagnostics, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	6.9%
2016	4	13.8%
2017	6	20.7%
2018	3	10.3%
2019	2	6.9%
2020	3	10.3%
2021	3	10.3%
2023	2	6.9%
2024	1	3.4%
2025partial year	3	10.3%

Which technologies does Longhorn Vaccines and Diagnostics, LLC patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 21

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 15

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 14

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

C07K - Peptides 11

Y02A - Technologies FOR Adaptation TO Climate Change 6

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 2

C12Y - Enzymes 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 2

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Longhorn Vaccines and Diagnostics, LLC's patent record in context - here's where to go next.

Longhorn Vaccines and Diagnostics, LLC's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 72.4% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #10,672 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Longhorn Vaccines and Diagnostics, LLC against Locix, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.